Robert Margolis - DaVita HealthCare Co-Chairman of the Board
| DVA Stock | USD 126.11 1.53 1.20% |
Chairman
Dr. Robert J. Margolis is CoChairman of the Board of DaVita HealthCare Partners Inc. Dr. Margolis became cochairman of the Board in November 2012 in connection with acquisition of HCP LLC. He served as the chief executive officer of HCP LLC from May 1982 to November 2012 and as the chief executive officer of our integrated care business HealthCare Partners from November 2012 to March 2014. Dr. Margolis is board certified in internal medicine and medical oncology having trained at Duke University Medical School and the National Cancer Institute. Dr. Margolis serves on the boards of the Martin Luther King Hospital the National Committee for Quality Assurance the California Association of Physician Groups and the California Hospital Medical Center Foundation Los Angeles. Dr. Margolis also serves as a member of HealthCare Policy Advisory Council for Harvard Medical School and as a member of the advisory board of the USC Schaeffer Center for Health Policy and Economics. Dr. Margolis previously served as the chairman of the boards of the American Medical Group Association the National Committee for Quality Assurance and the Unified Medical Group Association. Dr. Margolis has a national reputation in the managed care industry with over 40 years of industry experience. since 2012.
| Age | 68 |
| Tenure | 12 years |
| Address | 2000 16th Street, Denver, CO, United States, 80202 |
| Phone | 720 631 2100 |
| Web | https://www.davita.com |
DaVita HealthCare Management Efficiency
The company has Return on Asset of 0.0592 % which means that on every $100 spent on assets, it made $0.0592 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.3853 %, implying that it generated $0.3853 on every 100 dollars invested. DaVita HealthCare's management efficiency ratios could be used to measure how well DaVita HealthCare manages its routine affairs as well as how well it operates its assets and liabilities. At present, DaVita HealthCare's Return On Tangible Assets are projected to slightly decrease based on the last few years of reporting. The current year's Return On Capital Employed is expected to grow to 0.15, whereas Return On Assets are forecasted to decline to 0.04. At present, DaVita HealthCare's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Return On Tangible Assets is expected to grow to 0.07, whereas Total Assets are forecasted to decline to about 10.6 B.Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| Robert Frist | HealthStream | 57 | |
| Wyche III | Streamline Health Solutions | 52 | |
| Frank Williams | Evolent Health | 58 | |
| Walter Woltosz | Simulations Plus | 70 | |
| Jonathan Phillips | Streamline Health Solutions | 44 | |
Management Performance
| Return On Equity | 0.39 | ||||
| Return On Asset | 0.0592 |
DaVita HealthCare Leadership Team
Elected by the shareholders, the DaVita HealthCare's board of directors comprises two types of representatives: DaVita HealthCare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DaVita. The board's role is to monitor DaVita HealthCare's management team and ensure that shareholders' interests are well served. DaVita HealthCare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DaVita HealthCare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Hearty, Chief Compliance Officer | ||
| Shawn Guertin, Director | ||
| Javier Rodriguez, Chief Executive Officer, Director | ||
| Paula Price, Independent Director | ||
| James Hilger, Interim CFO and Chief Accounting Officer | ||
| Paul Diaz, Independent Director | ||
| Misha Palecek, Chief Business | ||
| Christopher Berry, Group Officer | ||
| Jeffrey Giullian, Chief Care | ||
| Robert Lang, President International Business | ||
| John Nehra, Independent Director | ||
| Peter Grauer, Lead Independent Director | ||
| Phyllis Yale, Independent Director | ||
| Craig Samitt, Executive Vice President; CEO of HealthCare Partners | ||
| Robert Margolis, Co-Chairman of the Board | ||
| Joseph Mello, COO of HealthCare Partners | ||
| Jim Gustafson, Vice President - Investor Relations | ||
| John Winstel, Chief Accounting Officer, Group Vice President | ||
| Roger Valine, Independent Director | ||
| Kenneth Smith, Chief Officer | ||
| Gregory Moore, Independent Director | ||
| David Roer, Chief Medical Officer - DaVita Integrated Kidney Care | ||
| FRCPC MD, Chief Operations | ||
| Atul Mathur, Executive Vice President of Global Operations | ||
| Joel Ackerman, Chief Financial Officer, Treasurer | ||
| Kathleen Waters, Chief Legal and Public Affairs Officer | ||
| Pamela Arway, Independent Chairman of the Board | ||
| Michael Staffieri, Chief Operating Officer- DaVita Kidney Care | ||
| Pascal Desroches, Independent Director | ||
| LeAnne Zumwalt, Group Vice President - purchasing and government affairs | ||
| Kenny Gardner, Chief People Officer - DaVita Kidney Care | ||
| Kim Rivera, Chief Legal Officer | ||
| Carol Davidson, Independent Director | ||
| Barbara Desoer, Independent Director | ||
| Dennis Kogod, CEO of International and President of Healthcare Partners | ||
| William Roper, Independent Director | ||
| Mihran Naljayan, Chief Medical Officer - Home Modalities | ||
| Charles Berg, Independent Director | ||
| Jeanine Jiganti, Chief Compliance Officer | ||
| Laura Mildenberger, Chief People Officer - Kidney Care | ||
| MSc MD, Chief International | ||
| Kent Thiry, Chairman, CEO and CEO of Healthcare Partners |
DaVita Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DaVita HealthCare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.39 | ||||
| Return On Asset | 0.0592 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 23.79 B | ||||
| Shares Outstanding | 87.32 M | ||||
| Shares Owned By Insiders | 45.06 % | ||||
| Shares Owned By Institutions | 51.58 % | ||||
| Number Of Shares Shorted | 4.14 M | ||||
| Price To Earning | 11.43 X |
Pair Trading with DaVita HealthCare
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DaVita HealthCare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DaVita HealthCare will appreciate offsetting losses from the drop in the long position's value.Moving together with DaVita Stock
| 0.95 | ELMD | Electromed | PairCorr |
| 0.84 | ALC | Alcon AG Financial Report 14th of May 2024 | PairCorr |
| 0.89 | BAX | Baxter International Financial Report 25th of April 2024 | PairCorr |
Moving against DaVita Stock
| 0.94 | IVP | Inspire Veterinary | PairCorr |
| 0.82 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
| 0.81 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
| 0.79 | NVST | Envista Holdings Corp Financial Report 1st of May 2024 | PairCorr |
| 0.77 | MMSI | Merit Medical Systems Financial Report 24th of April 2024 | PairCorr |
The ability to find closely correlated positions to DaVita HealthCare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DaVita HealthCare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DaVita HealthCare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DaVita HealthCare Partners to buy it.
The correlation of DaVita HealthCare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DaVita HealthCare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DaVita HealthCare moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DaVita HealthCare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DaVita HealthCare Partners. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for DaVita Stock analysis
When running DaVita HealthCare's price analysis, check to measure DaVita HealthCare's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DaVita HealthCare is operating at the current time. Most of DaVita HealthCare's value examination focuses on studying past and present price action to predict the probability of DaVita HealthCare's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DaVita HealthCare's price. Additionally, you may evaluate how the addition of DaVita HealthCare to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is DaVita HealthCare's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DaVita HealthCare. If investors know DaVita will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DaVita HealthCare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.2 | Earnings Share 7.42 | Revenue Per Share 133.717 | Quarterly Revenue Growth 0.078 | Return On Assets 0.0592 |
The market value of DaVita HealthCare is measured differently than its book value, which is the value of DaVita that is recorded on the company's balance sheet. Investors also form their own opinion of DaVita HealthCare's value that differs from its market value or its book value, called intrinsic value, which is DaVita HealthCare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DaVita HealthCare's market value can be influenced by many factors that don't directly affect DaVita HealthCare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DaVita HealthCare's value and its price as these two are different measures arrived at by different means. Investors typically determine if DaVita HealthCare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DaVita HealthCare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.